The aspect of Pfizer's coronavirus vaccine that really stunned the company's scientists was the fact that vaccinated participants in the Phase 3 efficacy trial had protections against the pathogen by day 12, a time at which there was barely any antibody response, Stat News reports. "That was the biggest surprise," said Vidia Roopchand, Pfizer's principal scientist for viral vaccines.
Roopchand is still trying to figure exactly why that is — not that it's a bad thing — by poring over the data. One possibility is that other aspects of the immune system such as T-cells that Roopchand says have largely been neglected in immunology research may have played a significant role. It's possible, he suggested, that's more important to measure cellular immunity than look for a robust antibody response. "The 12-day protection data is telling us there's more to it," Roopchand told Stat. "This is a great time to learn."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
5 sunny-side up cartoons about egg pricesCartoons Artists take on inflated prices, double standards, and more
-
'Swimming in the sky' in northern BrazilThe Week Recommends The pools of Lençóis Maranhenses are clear and blue
-
An ailing Pope Francis – and the vultures circling in the VaticanTalking Point Caught between his progressive inner circle and an influx of conservatism, the Holy Father should 'brace' himself for a battle
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
How close are we to a norovirus vaccine?Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
-
HMPV is spreading in China but there's no need to worryThe Explainer Respiratory illness is common in winter
-
Marty Makary: the medical contrarian who will lead the FDAIn the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
-
Dark chocolate tied to lower diabetes riskSpeed Read The findings were based on the diets of about 192,000 US adults over 34 years
